Arcadia Biosciences, Inc.
RKDA
$0.47
$0.000.23%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 31.18% | 22.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 31.18% | 22.09% | |||
| Cost of Revenue | 16.00% | -1.27% | |||
| Gross Profit | 57.75% | 108.33% | |||
| SG&A Expenses | -4.41% | -24.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.19% | -17.44% | |||
| Operating Income | 36.33% | 43.35% | |||
| Income Before Tax | -42.90% | -230.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -42.90% | -228.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -42.90% | -228.22% | |||
| EBIT | 36.33% | 43.35% | |||
| EBITDA | 35.67% | 43.85% | |||
| EPS Basic | 0.54% | -116.19% | |||
| Normalized Basic EPS | 15.26% | -41.21% | |||
| EPS Diluted | 0.76% | -115.83% | |||
| Normalized Diluted EPS | 15.26% | -41.21% | |||
| Average Basic Shares Outstanding | 43.67% | 51.83% | |||
| Average Diluted Shares Outstanding | 43.67% | 51.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||